Transcription activator BRG1 (SMARCA4)-mutated tumors are also very common recurrent alterations in NSCLC and are characterized by higher TMB and low or negative PD-L1, while the use of ICIs is associated with significantly improved survival [112]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.